MannKind stock today

Article Index

MannKind Corp. (Nasdaq: MNKD) Stock Doubles on Drug News - Can Gains Continue?

MannKind Corp. (Nasdaq: MNKD) stock doubled Wednesday after its inhaled diabetes treatment, Afrezza, was recommended for approval by a Food and Drug Administration (FDA) advisory committee.

In a unanimous 14 to 0 thumbs-up, the group voted Afrezza should be approved for type 2 diabetes, the more common form of the blood sugar disease. In a near-united nod, the group voted 13 to 1 in favor of Afrezza's approval for type 1 diabetes.

Here’s what investors need to know…